Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | Three months ended March 31, 2026 | 2025 |
|---|---|---|
| Total revenues | 60,112 | 32,704 |
| Costs and expenses: | ||
| Cost of sales | 7,157 | 3,648 |
| Research and development | 41,725 | 36,973 |
| Selling, general, and administrative | 63,591 | 39,087 |
| Total costs and expenses | 112,473 | 79,708 |
| Loss from operations | (52,361) | (47,004) |
| Other income (expense): |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s R&D?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported R&D of $41.73M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s R&D changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s R&D increased by 12.9% year-over-year, from $36.97M to $41.73M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s R&D?
- Over 4 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s R&D has grown at a 12.6% compound annual growth rate (CAGR), from $104.13M to $167.34M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude